References

Unresolved reference

2024 · External reference

Azacitidine and venetoclax in previously untreated acute myeloid leukemia

10.1056/nejmoa2012971 · 2020 · External reference

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

10.1182/blood.2020004856 · 2020 · External reference

Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: comparative analysis of response, toxicity, and survival

2023 · External reference

Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia

10.1002/cncr.33508 · 2021 · External reference

Invasive fungal infection following venetoclax and posaconazole co-administration

10.1111/bjh.19116 · 2023 · External reference

ELN risk stratification is not predictive of outcomes for treatment-naïve patients with acute myeloid leukemia treated with venetoclax and azacitidine

10.1182/blood-2022-169509 · 2022 · External reference

Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax

10.1182/bloodadvances.2023011757 · 2024 · External reference

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

10.1182/blood-2009-11-254441 · 2010 · External reference

Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: genotype signatures for response and survival among 301 consecutive patients

10.1002/ajh.27138 · 2024 · External reference

Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia

10.1182/bloodadvances.2019000243 · 2019 · External reference

Novel stratification for newly diagnosed acute myeloid leukaemia treated with venetoclax-based therapy in the real world: Hokkaido Leukemia Net Study

10.1111/bjh.19292 · 2024 · External reference

Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia

10.1002/ajh.26991 · 2023 · External reference

Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice

10.1002/ajh.26190 · 2021 · External reference

Venetoclax and hypomethylating agents as first-line treatment in newly diagnosed patients with AML in a predominately community setting in the US

10.1093/oncolo/oyac135 · 2022 · External reference

Outcomes of newly diagnosed acute myeloid leukemia patients treated with hypomethylating agents with or without venetoclax: a Propensity Score-Adjusted Cohort Study

10.3389/fonc.2022.858202 · 2022 · External reference

Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia

10.1182/bloodadvances.2021005538 · 2021 · External reference

Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience

10.1016/j.leukres.2022.106803 · 2022 · External reference

Clinical outcomes of hypomethylating agents plus venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: real-world data from eight US academic centers

10.1002/ajh.27231 · 2024 · External reference

Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy

10.1182/blood.2023021579 · 2024 · External reference

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

10.1182/blood-2016-08-733196 · 2017 · External reference

Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel

10.1182/blood.2022016867 · 2022 · External reference

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

10.1182/blood.2019003988 · 2020 · External reference

Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia

10.1002/ajh.27246 · 2024 · External reference

Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy

10.1182/blood.2022016963 · 2022 · External reference

Venetoclax with hypomethylating agents in newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis of survival data from real-world studies

10.3390/cancers15184618 · 2023 · External reference

Cytogenetic and molecular associations with outcomes in HR-MDS treated with hypomethylating agents plus venetoclax

10.1158/1078-0432.ccr-23-2860 · 2024 · External reference

Impact of FLT3 mutation on outcomes after venetoclax and azacitidine for patients with treatment-naive acute myeloid leukemia

10.1158/1078-0432.ccr-21-3405 · 2022 · External reference

Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens

10.1182/bloodadvances.2019001267 · 2020 · External reference

Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML

10.1182/bloodadvances.2023011106 · 2024 · External reference

Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): a phase Ib dose-escalation study of venetoclax combined with modified intensive chemotherapy

10.1200/jco.20.00572 · 2020 · External reference